Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity. It ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called GLP-1.

The U.S. Food and Drug ... sleep apnea (OSA) in adults with obesity. Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...